Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 28, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions

GlioblastomaRecurrent Glioblastoma

Interventions

DRUG

Avutometinib

Given PO

PROCEDURE

Biospecimen Collection

Undergo blood and tissue sample collection

DRUG

Defactinib

Given PO

Trial Locations (1)

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Verastem, Inc.

INDUSTRY

lead

Emory University

OTHER